Shares of OmniAb, Inc. (NASDAQ:OABI – Get Rating) have received an average recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $10.29.
Several research analysts recently weighed in on OABI shares. Cowen assumed coverage on shares of OmniAb in a report on Wednesday, February 22nd. They set an “outperform” rating and a $10.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of OmniAb in a research report on Monday, November 28th. They issued a “buy” rating and a $12.00 price target on the stock. Truist Financial began coverage on OmniAb in a research note on Tuesday, December 20th. They set a “buy” rating and a $10.00 price objective for the company. Cowen assumed coverage on OmniAb in a research note on Wednesday, February 22nd. They set an “outperform” rating and a $10.00 price target for the company. Finally, Credit Suisse Group assumed coverage on OmniAb in a report on Friday, December 16th. They issued an “outperform” rating and a $13.00 price objective on the stock.
OmniAb Stock Performance
OmniAb stock opened at $3.43 on Friday. OmniAb has a fifty-two week low of $1.91 and a fifty-two week high of $10.50. The stock’s 50-day moving average price is $3.89.
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Get a free copy of the StockNews.com research report on OmniAb (OABI)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.